Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-25-007112
Filing Date
2025-03-05
Accepted
2025-03-05 20:30:05
Documents
1
Period of Report
2025-03-04

Document Format Files

Seq Description Document Type Size
1 form4-03052025_080301.html 4  
1 form4-03052025_080301.xml 4 4418
  Complete submission text file 0001415889-25-007112.txt   5901
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Issuer) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O KEZAR LIFE SCIENCES, INC. 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address
Schiller Mark C. (Reporting) CIK: 0002007659 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38542 | Film No.: 25713275